Latest Tempest Therapeutics News & Updates

See the latest news and media coverage for Tempest. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Tempest Therapeutics (Tempest)

Clinical-stage CAR T biotechnology company

tempesttx.com
Headquarters
Brisbane, United States
Company type
Public company
Number of employees
11–50
Industry
Pharmaceuticals

Last updated

Latest news about Tempest Therapeutics (Tempest)

In short: Tempest licensed Senlang’s CAR-T platform as third-quarter results showed $0.9 million cash and going-concern doubt

Company announcements

Tempest

Tempest Therapeutics reports 2025 financial results and business updates

The company reported a net loss of $26.3 million, acquired CAR-T assets from Factor Bioscience, appointed a new CEO, and announced positive interim data for TPST-2003.

Unlock all announcements with a

Media coverage

StreetInsider

Tempest Therapeutics options CD7 lentiviral CAR-T platform from Senlang

Tempest Therapeutics (Nasdaq: TPST) has entered into an exclusive option agreement with Hebei Senlang Biotechnology Co., Ltd. to potentially license Senlang's CD7-targeted lentiviral vector platform...

Unlock all articles with a

Never miss news about Tempest

Track Tempest and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.